Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
Open Access
- 15 November 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (10), 1260-1269
- https://doi.org/10.1086/592579
Abstract
Background. Comparable sustained virologic response (SVR) rates have been documented between Asian patients who received 24 weeks of pegylated interferon (IFN) plus ribavirin and white patients who received 48 weeks of combination therapy for hepatitis C virus genotype 1 (HCV-1) infection. Whether a 48-week course of combination therapy shows a better SVR rate than a 24-week course of such therapy among Asian patients with HCV-1 infection has not been confirmed in multicenter, randomized studies. Methods. In this multicenter, randomized trial, 308 treatment-naive HCV-1-infected Asian patients were randomly assigned to receive either 24 or 48 weeks of pegylated IFN-α-2a (180 µg per week) plus ribavirin (1000–1200 mg/day) therapy. The primary end point was SVR, defined as an undetectable serum HCV RNA level 24 weeks after discontinuation of therapy. In addition, rapid virologic response (RVR) was defined as an undetectable serum HCV RNA level at week 4 of therapy, and complete early virologic response was defined as an undetectable serum HCV RNA level at 12 weeks of therapy in the absence of RVR. Results. By intention-to-treat analysis, patients who received 48 weeks of therapy had a significantly higher SVR rate than did those who received 24 weeks of therapy (76% vs. 56%; P<.001). Among patients with a baseline serum HCV RNA level P=.13). In contrast, 48 weeks of therapy was associated with a significantly higher SVR rate than was 24 weeks of therapy among patients without RVR (39% vs.16%; P=.01) and among those who achieved a complete early virologic response (44% vs. 20%; P=.02). Conclusions. In treatment-naive Asian patients with HCV-1 infection, 48 weeks of pegylated IFN-α-2a plus ribavirin therapy is associated with a higher SVR rate, compared with 24 weeks of such therapy. Patients with a baseline serum HCV RNA level Clinical trials registration. NCT00495131.This publication has 36 references indexed in Scilit:
- Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trialHepatology, 2008
- Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2007
- Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirinJournal of Gastroenterology and Hepatology, 2007
- A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in TaiwanLiver International, 2005
- Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in TaiwanJournal of Viral Hepatitis, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Hepatitis C Virus InfectionThe New England Journal of Medicine, 2001
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995